Pharsight

1. List of Steglujan drug patents

Application	Filing Date	Opposition Party	Legal Status
EP05077584A	2011-03-15	APOTEX INC.	Revoked
EP04755691A	2008-06-11	Teva Pharmaceutical Industries Ltd.	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US7326708	June, 2020	FWD Entered	Merck Sharp & Dohme Corp.	Sun Pharmaceutical Industries Ltd.
US7326708	June, 2020	FWD Entered	Merck Sharp & Dohme Corp.	Dr. Reddy's Laboratories, Inc.
US7326708	June, 2020	Terminated-Settled	Merck Sharp & Dohme Corp.	Teva Pharmaceuticals USA, Inc.
US7326708	October, 2019	FWD Entered	Merck Sharp & Dohme Corp.	Mylan Pharmaceuticals, Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jul, 2022 (7 months ago)
US7326708	MERCK SHARP DOHME	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	Nov, 2026 (3 years from now)
US8080580	MERCK SHARP DOHME	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	Jul, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871 (Pediatric)	MERCK SHARP DOHME	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	Jan, 2023 (a month ago)
US7326708 (Pediatric)	MERCK SHARP DOHME	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	May, 2027 (4 years from now)
US9439901	MERCK SHARP DOHME	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	Oct, 2030 (7 years from now)
US9308204	MERCK SHARP DOHME	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	Oct, 2030 (7 years from now)